Cargando…

Liver-specific knockout of arginase-1 leads to a profound phenotype similar to inducible whole body arginase-1 deficiency

Arginase-1 (Arg1) converts arginine to urea and ornithine in the distal step of the urea cycle in liver. We previously generated a tamoxifen-inducible Arg1 deficient mouse model (Arg1-Cre) that disrupts Arg1 expression throughout the whole body and leads to lethality ≈ 2 weeks after gene disruption....

Descripción completa

Detalles Bibliográficos
Autores principales: Ballantyne, Laurel L., Sin, Yuan Yan, Al-Dirbashi, Osama Y., Li, Xinzhi, Hurlbut, David J., Funk, Colin D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065044/
https://www.ncbi.nlm.nih.gov/pubmed/27761413
http://dx.doi.org/10.1016/j.ymgmr.2016.10.003
_version_ 1782460259858644992
author Ballantyne, Laurel L.
Sin, Yuan Yan
Al-Dirbashi, Osama Y.
Li, Xinzhi
Hurlbut, David J.
Funk, Colin D.
author_facet Ballantyne, Laurel L.
Sin, Yuan Yan
Al-Dirbashi, Osama Y.
Li, Xinzhi
Hurlbut, David J.
Funk, Colin D.
author_sort Ballantyne, Laurel L.
collection PubMed
description Arginase-1 (Arg1) converts arginine to urea and ornithine in the distal step of the urea cycle in liver. We previously generated a tamoxifen-inducible Arg1 deficient mouse model (Arg1-Cre) that disrupts Arg1 expression throughout the whole body and leads to lethality ≈ 2 weeks after gene disruption. Here, we evaluate if liver-selective Arg1 loss is sufficient to recapitulate the phenotype observed in global Arg1 knockout mice, as well as to gauge the effectiveness of gene delivery or hepatocyte transplantation to rescue the phenotype. Liver-selective Arg1 deletion was induced by using an adeno-associated viral (AAV)-thyroxine binding globulin (TBG) promoter-Cre recombinase vector administered to Arg1 “floxed” mice; Arg1(fl/fl)). An AAV vector expressing an Arg1-enhanced green fluorescent protein (Arg1-eGFP) transgene was used for gene delivery, while intrasplenic injection of wild-type (WT) C57BL/6 hepatocytes after partial hepatectomy was used for cell delivery to “rescue” tamoxifen-treated Arg1-Cre mice. The results indicate that liver-selective loss of Arg1 (> 90% deficient) leads to a phenotype resembling the whole body knockout of Arg1 with lethality ≈ 3 weeks after Cre-induced gene disruption. Delivery of Arg1-eGFP AAV rescues more than half of Arg1 global knockout male mice (survival > 4 months) but a significant proportion still succumb to the enzyme deficiency even though liver expression and enzyme activity of the fusion protein reach levels observed in WT animals. Significant Arg1 enzyme activity from engrafted WT hepatocytes into knockout livers can be achieved but not sufficient for rescuing the lethal phenotype. This raises a conundrum relating to liver-specific expression of Arg1. On the one hand, loss of expression in this organ appears to be both necessary and sufficient to explain the lethal phenotype of the genetic disorder in mice. On the other hand, gene and cell-directed therapies suggest that rescue of extra-hepatic Arg1 expression may also be necessary for disease correction. Further studies are needed in order to illuminate the detailed mechanisms for pathogenesis of Arg1-deficiency.
format Online
Article
Text
id pubmed-5065044
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-50650442016-10-19 Liver-specific knockout of arginase-1 leads to a profound phenotype similar to inducible whole body arginase-1 deficiency Ballantyne, Laurel L. Sin, Yuan Yan Al-Dirbashi, Osama Y. Li, Xinzhi Hurlbut, David J. Funk, Colin D. Mol Genet Metab Rep Research Paper Arginase-1 (Arg1) converts arginine to urea and ornithine in the distal step of the urea cycle in liver. We previously generated a tamoxifen-inducible Arg1 deficient mouse model (Arg1-Cre) that disrupts Arg1 expression throughout the whole body and leads to lethality ≈ 2 weeks after gene disruption. Here, we evaluate if liver-selective Arg1 loss is sufficient to recapitulate the phenotype observed in global Arg1 knockout mice, as well as to gauge the effectiveness of gene delivery or hepatocyte transplantation to rescue the phenotype. Liver-selective Arg1 deletion was induced by using an adeno-associated viral (AAV)-thyroxine binding globulin (TBG) promoter-Cre recombinase vector administered to Arg1 “floxed” mice; Arg1(fl/fl)). An AAV vector expressing an Arg1-enhanced green fluorescent protein (Arg1-eGFP) transgene was used for gene delivery, while intrasplenic injection of wild-type (WT) C57BL/6 hepatocytes after partial hepatectomy was used for cell delivery to “rescue” tamoxifen-treated Arg1-Cre mice. The results indicate that liver-selective loss of Arg1 (> 90% deficient) leads to a phenotype resembling the whole body knockout of Arg1 with lethality ≈ 3 weeks after Cre-induced gene disruption. Delivery of Arg1-eGFP AAV rescues more than half of Arg1 global knockout male mice (survival > 4 months) but a significant proportion still succumb to the enzyme deficiency even though liver expression and enzyme activity of the fusion protein reach levels observed in WT animals. Significant Arg1 enzyme activity from engrafted WT hepatocytes into knockout livers can be achieved but not sufficient for rescuing the lethal phenotype. This raises a conundrum relating to liver-specific expression of Arg1. On the one hand, loss of expression in this organ appears to be both necessary and sufficient to explain the lethal phenotype of the genetic disorder in mice. On the other hand, gene and cell-directed therapies suggest that rescue of extra-hepatic Arg1 expression may also be necessary for disease correction. Further studies are needed in order to illuminate the detailed mechanisms for pathogenesis of Arg1-deficiency. Elsevier 2016-10-12 /pmc/articles/PMC5065044/ /pubmed/27761413 http://dx.doi.org/10.1016/j.ymgmr.2016.10.003 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Ballantyne, Laurel L.
Sin, Yuan Yan
Al-Dirbashi, Osama Y.
Li, Xinzhi
Hurlbut, David J.
Funk, Colin D.
Liver-specific knockout of arginase-1 leads to a profound phenotype similar to inducible whole body arginase-1 deficiency
title Liver-specific knockout of arginase-1 leads to a profound phenotype similar to inducible whole body arginase-1 deficiency
title_full Liver-specific knockout of arginase-1 leads to a profound phenotype similar to inducible whole body arginase-1 deficiency
title_fullStr Liver-specific knockout of arginase-1 leads to a profound phenotype similar to inducible whole body arginase-1 deficiency
title_full_unstemmed Liver-specific knockout of arginase-1 leads to a profound phenotype similar to inducible whole body arginase-1 deficiency
title_short Liver-specific knockout of arginase-1 leads to a profound phenotype similar to inducible whole body arginase-1 deficiency
title_sort liver-specific knockout of arginase-1 leads to a profound phenotype similar to inducible whole body arginase-1 deficiency
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065044/
https://www.ncbi.nlm.nih.gov/pubmed/27761413
http://dx.doi.org/10.1016/j.ymgmr.2016.10.003
work_keys_str_mv AT ballantynelaurell liverspecificknockoutofarginase1leadstoaprofoundphenotypesimilartoinduciblewholebodyarginase1deficiency
AT sinyuanyan liverspecificknockoutofarginase1leadstoaprofoundphenotypesimilartoinduciblewholebodyarginase1deficiency
AT aldirbashiosamay liverspecificknockoutofarginase1leadstoaprofoundphenotypesimilartoinduciblewholebodyarginase1deficiency
AT lixinzhi liverspecificknockoutofarginase1leadstoaprofoundphenotypesimilartoinduciblewholebodyarginase1deficiency
AT hurlbutdavidj liverspecificknockoutofarginase1leadstoaprofoundphenotypesimilartoinduciblewholebodyarginase1deficiency
AT funkcolind liverspecificknockoutofarginase1leadstoaprofoundphenotypesimilartoinduciblewholebodyarginase1deficiency